New combo therapy aims to boost leukemia remission with fewer side effects
NCT ID NCT06387121
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new treatment approach for adults newly diagnosed with a specific type of leukemia (Ph-negative B-cell acute lymphoblastic leukemia). The treatment combines low-dose chemotherapy with several targeted immunotherapy drugs. The goal is to see if this gentler regimen can help more patients achieve a deep remission (no detectable cancer cells) and improve long-term survival. The study will enroll 53 adults and track their response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of low-dose chemotherapy (vincristine, cyclophosphamide, dexamethasone, 6-mercaptopurine, methotrexate) and immuno-targeted drugs (venetoclax, inotuzumab ozogamicin, blinatumomab)
- What this could lead to
- If successful, this could offer a more tolerable and effective treatment option for adults with B-cell acute lymphoblastic leukemia, potentially improving remission rates and survival without the need for intensive chemotherapy.
- What could go wrong
- This is a small, early-phase (phase 2) single-arm study with only 53 participants, so results may not apply to all patients. The combination of drugs may still cause significant side effects, and the treatment may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual play therapy aims to boost motor skills and social life in young leukemia survivors
- Can a smart patch predict dangerous immune reactions in cancer treatment?
- Healing harmonies: music therapy aims to ease stem cell transplant recovery
- CAR-T cells take on stubborn leukemia after transplant in new trial
- Experimental CART123 therapy targets tough blood cancers in early trial
- One-Time infusion aims to build cancer killers inside the body